a6352770.htm

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
 
FORM 8-K/A
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):
 
April 30, 2010
 
 
LANDEC CORPORATION
(Exact name of registrant as specified in its charter)
 
Delaware
  
0-27446
  
94-3025618
(State or other jurisdiction
of incorporation)
  
(Commission File Number)
  
(IRS Employer
Identification No.)
 
3603 Haven Avenue
Menlo Park, CA 94025
(Address of principal executive offices, including zip code)
 
(650) 306-1650
(Registrant’s telephone number, including area code)
 
Not Applicable
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Amendment No. 1
 
This Form 8-K/A is filed as an amendment (Amendment No. 1) to the Current Report on Form 8-K filed by Landec Corporation under Items 1.01, 2.01, 2.03 and 9.01 on May 5, 2010.  Amendment No. 1 is being filed to include the financial information required under Item 9.01.
 
 
 
 
 
 
Item 9.01.
Financial Statements and Exhibits.
 
(a)  Financial Statements of Business Acquired.
 
The audited financial statements of Lifecore Biomedical, Inc. as of December 31, 2009 and 2008 and for the periods then ended are filed as Exhibit 99.1 hereto and incorporated herein by this reference.
 
(b)  Pro Forma Financial Information.
 
The pro forma financial information with respect to the transaction described in Item 2.01 of the Current Report on Form 8-K filed on May 5, 2010 is filed as Exhibit 99.2 hereto and incorporated herein by this reference.
 
(d)  Exhibits.
 
Exhibit No.
  
Description
     
23.1
  
Consent of Grant Thornton LLP, Independent Certified Public Accountants
     
99.1
  
Audited financial statements of Lifecore Biomedical, LLC as of December 31, 2009 and 2008 and for the periods then ended
     
99.2
  
Unaudited pro forma condensed combined financial statements of Landec Corporation and Lifecore Biomedical, Inc.
 
 
 
2
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
LANDEC CORPORATION
       
Date: July 9, 2010
 By:
 
/s/ Gregory S. Skinner
     
Gregory S. Skinner
     
Chief Financial Officer
 
 
 
3
 
 
EXHIBIT INDEX
 
Exhibit No.
  
Description
     
23.1
  
Consent of Grant Thornton LLP, Independent Certified Public Accountants
     
99.1
  
Audited financial statements of Lifecore Biomedical, LLC as of December 31, 2009 and 2008 and for the periods then ended
     
99.2
  
Unaudited pro forma condensed combined financial statements of Landec Corporation and Lifecore Biomedical, Inc.
 
 
 
4